Way behind ARQL's tivantinib. How is INCY's MET inhibitor differentiated?
I haven't been great at following this space, but it seems to me that time is not the essence in determining who is ahead in the MET field. Rather, the company that best executes on identifying the population to test will win the day.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.